The in vivo efficacy of BTK-IN-8 was evaluated using the MLL-AF9 leukemia mouse model, where two treatment arms were implemented: a control vehicle group and a BTK-IN-8 treatment group (4 mg/kg daily) (Figure 7P). The gene discussed is KMT2A; the disease is leukemia.